Research is a beginning of pharmaceutical innovation. Contract Research Organizations (CROs) are tasked with overcoming a unique set of challenges to ensure the success of drug developement. One primary obstacle is the acquisition of suitable new technologies to expand research capacity, as outdated or insufficient methods can hinder progress. Furthermore, the investment in fixed assets brings an element of uncertainty, as returns on these investments are not guaranteed. CROs also face the ongoing challenge of identifying and securing new projects to maintain a robust portfolio and sustained growth, necessitating a proactive approach to business development.